Glycomine’s Series C raise highlights investor confidence in the company amid pressure on the paediatric rare disease sector.

Eisai and Biogen have received marketing authorisation from the European Commission (EC) for Leqembi (lecanemab) to treat ...

The executive order aims to lower prescription prices, but targets the mechanism for negotiating small molecule drug costs.

The agreement is seen as a win for global health ahead of the US withdrawal from the WHO and amidst foreign aid cuts by the ...

Our editorial team dissects the latest developments in the ongoing story of how evolving US tariffs could impact the ...

Telehealth providers, whose revenue skyrocketed amidst GLP-1 shortages, remain defiant on their compounded semaglutide ...

Mural Oncology is halting development of its lead IL-2 therapy and enacting major layoffs after its second trial failure this ...

Irish medical and pharmaceutical exports to the US have seen a surge, with a year-on-year increase above 450% in February ...

Boehringer and Cue Biopharma have entered a strategic research partnership and licence agreement for the latter’s CUE-501.

AD is a growing market with an impressive pipeline of new products from current and future players in the field.

J&J is projecting a $400m hit due to US tariffs in 2025, but reaffirmed its profit outlook while raising its sales forecast.

Phase Ib results show VERVE-102 reduced LDL-C levels with no serious safety issues, unlike Verve’s VERVE-101 programme.